Company Profile
ChiRhoClin, Inc., a Maryland based family run corporation founded in 1991 by Dr. Edward D. Purich, is a research and development oriented pharmaceutical company focused on developing orphan drug products for the gastrointestinal and radiological community. Our emphasis is to develop orphan drug products that will diagnose and treat pancreatic gastrointestinal diseases and encourage research in the pancreatic area through our small pancreatic grant program.
ChiRhoClin, Inc. received approval from the FDA on April 5, 2002 to manufacture and market synthetic porcine secretin.
ChiRhoClin, Inc. received approval from the FDA on April 9th, 2004 to manufacture and market ChiRhoStim® (Human Secretin for injection).
Our lead product, ChiRhoStim® is approved for Pancreatic Function Testing, facilitating cannulation during ERCP, and Gastrinoma Testing. In addition, secretions of the pancreatic fluid after secretin stimulation can be used in situ for imaging modalities such as MRCP, CT, and EUS.
ChiRhoStim® (Human Secretin for Injection) is now commercially availableChiRhoStim® is now reimbursable with J-Code 2850
Access Human Secretin for Injection package insert at the Products section.
To order, contact your wholesaler or call 1-877-CRC-4888.
For more information please visit www.ChiRhoStim.com
